The first head-to-head trial is in. Zepbound produced 47% more weight loss than Wegovy. But there's more to the story — here's the full breakdown.
Both are excellent medications. The right choice depends on your specific health goals, existing conditions, and insurance coverage.
Published in the New England Journal of Medicine in early 2025, SURMOUNT-5 was the first randomized controlled trial to directly compare tirzepatide (Zepbound) vs semaglutide (Wegovy) for weight loss. Here are the key findings:
Source: SURMOUNT-5 trial, NEJM 2025. Results shown are approximate averages at 72 weeks at maximum doses.
| Factor | Wegovy | Zepbound |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| FDA Approval | Obesity / BMI ≥30 | Obesity / BMI ≥30 |
| Approved Year | 2021 | 2023 |
| Avg Weight Loss | ~14% | ~20% (47% more) |
| Max Dose | 2.4 mg/week | 15 mg/week |
| Titration Duration | 16 weeks to maintenance | 20 weeks to maintenance |
| Heart Disease Data | ✅ SELECT trial (20% reduction) | ⏳ Trial ongoing |
| List Price / Month | ~$1,349 | ~$1,059 |
| Self-Pay Option | ❌ No | ✅ Vials from $399/mo |
| Medicare Coverage (2026) | ✅ Yes | ✅ Yes |
| Nausea Rate | ~44% | ~44% |
| Injection Type | Single-use autoinjector | Single-use autoinjector |
| Dosing Frequency | Once weekly | Once weekly |
| Pediatric Approval | ✅ Ages 12+ (2023) | ❌ Adults only |
| Best For | Heart disease patients, teens, established cardiovascular benefit needed | Maximum weight loss, cost-conscious, self-pay patients |
You can get a GLP-1 prescription online through telehealth — no in-person visit required. These services connect you with licensed providers who can prescribe Wegovy, Zepbound, or whichever drug is right for you.
* Affiliate links — we may earn a commission. This does not affect our editorial content or drug recommendations.
For weight loss specifically — yes, the data is clear. SURMOUNT-5 showed tirzepatide produced 47% more weight loss than semaglutide in a direct head-to-head comparison at 72 weeks. That's a significant difference, not a marginal one. However, Wegovy has stronger cardiovascular outcome data, which matters for patients with existing heart disease.
Yes — switching is possible and increasingly common as patients seek more weight loss or better pricing. Your doctor will determine the appropriate starting dose of tirzepatide based on your current semaglutide dose and response. There's typically a brief transition period.
Side effect profiles are very similar — both cause nausea in roughly 44% of patients, with diarrhea, constipation, and vomiting also common. Some patients report that tirzepatide's GI effects feel slightly different, but neither drug is clearly "easier on the stomach" than the other. The slow titration protocol is the most effective way to minimize side effects on both.
If you have type 2 diabetes, you'd typically be prescribed Ozempic or Mounjaro (the diabetes-approved versions). Wegovy and Zepbound are the obesity-approved versions of the same drugs. For blood sugar control alongside weight loss, tirzepatide (Mounjaro/Zepbound) generally shows superior A1C reduction in trials compared to semaglutide.
Zepbound (tirzepatide) produces more weight loss on average - about 20-22% vs 15% for Wegovy (semaglutide). Zepbound targets two hormone receptors (GLP-1 and GIP).
Both have similar safety profiles. Zepbound may cause slightly more diarrhea; Wegovy may cause slightly more nausea. Neither is definitively safer than the other.
Both have similar list prices around $1,000-$1,300/month. Insurance coverage and savings cards vary. Check manufacturer websites for current patient assistance programs.